New stroke treatment targets Medium-Sized clots
NCT ID NCT07336927
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving a clot-busting drug directly into the brain artery, plus possibly removing the clot with a device, helps people with medium-sized stroke clots. About 614 participants who cannot receive standard IV clot-busters will be randomly assigned to either the new procedure or best medical care alone. The goal is to see if the procedure leads to better recovery and less disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tenecteplase (TNK) given directly into the artery, plus possible mechanical clot removal
- What this could lead to
- If successful, this could offer a new treatment option for stroke patients with medium-sized clots who cannot receive standard clot-busting drugs through a vein.
- What could go wrong
- This is an early-stage trial with no phase assigned, so results are uncertain. The procedure carries risks like bleeding or vessel damage, and the benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO MEDIUM-VESSEL-OCCLUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China